title: Robust inference for group sequential trials.
abstract: For ethical reasons, group sequential trials were introduced to allow trials to stop early in the event of extreme results. Endpoints in such trials are usually mortality or irreversible morbidity. For a given endpoint, the norm is to use a single test statistic and to use that same statistic for each analysis. This approach is risky because the test statistic has to be specified before the study is unblinded, and there is loss in power if the assumptions that ensure optimality for each analysis are not met. To minimize the risk of moderate to substantial loss in power due to a suboptimal choice of a statistic, a robust method was developed for nonsequential trials. The concept is analogous to diversification of financial investments to minimize risk. The method is based on combining P values from multiple test statistics for formal inference while controlling the type I error rate at its designated value.This article evaluates the performance of 2 P value combining methods for group sequential trials. The emphasis is on time to event trials although results from less complex trials are also included. The gain or loss in power with the combination method relative to a single statistic is asymmetric in its favor. Depending on the power of each individual test, the combination method can give more power than any single test or give power that is closer to the test with the most power. The versatility of the method is that it can combine P values from different test statistics for analysis at different times. The robustness of results suggests that inference from group sequential trials can be strengthened with the use of combined tests.
authors.affiliation: Global Blood Therapeutics, South San Francisco, CA, USA.
authors.forename: Jitendra
authors.initials: J
authors.lastname: Ganju
authors.affiliation: Takeda Pharmaceuticals, Deerfield, IL, USA.
authors.forename: Yunzhi
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Theravance Biopharma US, South San Francisco, CA, USA.
authors.forename: Kefei
authors.initials: K
authors.lastname: Zhou
mesh_terms: D002986:Clinical Trials as Topic / Q000941:ethics / Q000379:methods*; D003627:Data Interpretation, Statistical; D057239:Early Termination of Clinical Trials / Q000941:ethics; D023381:Endpoint Determination / Q000941:ethics / Q000379:methods*; D006801:Humans; D015233:Models, Statistical; D012107:Research Design; D012306:Risk; D013997:Time Factors
keywords: interim analyses; multiple test statistics; permutation method